JP7825636B2 - (s)-n-(3-(2-(((r)-1-ヒドロキシプロパン-2-イル)アミノ)-6-モルホリノピリジン-4-イル)-4-メチルフェニル)-3-(2,2,2-トリフルオロエチル)ピロリジン-1-カルボキサミドおよびその塩の固体状態での形態 - Google Patents
(s)-n-(3-(2-(((r)-1-ヒドロキシプロパン-2-イル)アミノ)-6-モルホリノピリジン-4-イル)-4-メチルフェニル)-3-(2,2,2-トリフルオロエチル)ピロリジン-1-カルボキサミドおよびその塩の固体状態での形態Info
- Publication number
- JP7825636B2 JP7825636B2 JP2023565206A JP2023565206A JP7825636B2 JP 7825636 B2 JP7825636 B2 JP 7825636B2 JP 2023565206 A JP2023565206 A JP 2023565206A JP 2023565206 A JP2023565206 A JP 2023565206A JP 7825636 B2 JP7825636 B2 JP 7825636B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- ray powder
- powder diffraction
- exhibits
- solid form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163178752P | 2021-04-23 | 2021-04-23 | |
| US63/178,752 | 2021-04-23 | ||
| PCT/US2022/025815 WO2022226221A1 (en) | 2021-04-23 | 2022-04-21 | Solid state forms of (s)-n-(3-(2-(((r)-1-hydroxypropan-2-yl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and salts thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024517431A JP2024517431A (ja) | 2024-04-22 |
| JP2024517431A5 JP2024517431A5 (cg-RX-API-DMAC7.html) | 2025-05-02 |
| JP7825636B2 true JP7825636B2 (ja) | 2026-03-06 |
Family
ID=83723159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023565206A Active JP7825636B2 (ja) | 2021-04-23 | 2022-04-21 | (s)-n-(3-(2-(((r)-1-ヒドロキシプロパン-2-イル)アミノ)-6-モルホリノピリジン-4-イル)-4-メチルフェニル)-3-(2,2,2-トリフルオロエチル)ピロリジン-1-カルボキサミドおよびその塩の固体状態での形態 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12692248B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4326255A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7825636B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240000540A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117529313A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022261159A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023021916A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3216258A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL307910A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023012521A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI922665B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022226221A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020371727B2 (en) | 2019-10-24 | 2026-01-22 | Pierre Fabre Medicament | Inhibitors of RAF kinases |
| US11377431B2 (en) | 2020-10-12 | 2022-07-05 | Kinnate Biopharma Inc. | Inhibitors of RAF kinases |
| TW202308645A (zh) | 2021-04-23 | 2023-03-01 | 美商奇奈特生物製藥公司 | 使用raf抑制劑之癌症治療 |
| JP7825636B2 (ja) | 2021-04-23 | 2026-03-06 | ピエール ファーブル メディカモン | (s)-n-(3-(2-(((r)-1-ヒドロキシプロパン-2-イル)アミノ)-6-モルホリノピリジン-4-イル)-4-メチルフェニル)-3-(2,2,2-トリフルオロエチル)ピロリジン-1-カルボキサミドおよびその塩の固体状態での形態 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016038581A1 (en) | 2014-09-12 | 2016-03-17 | Novartis Ag | Compounds and compositions as raf kinase inhibitors |
| WO2020198058A1 (en) | 2019-03-22 | 2020-10-01 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
| JP7626910B2 (ja) | 2019-10-24 | 2025-02-05 | ピエール ファーブル メディカモン | Rafキナーゼの阻害剤 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100477070B1 (ko) | 1994-03-25 | 2006-04-21 | 이소테크니카 인코포레이티드 | 중수소화작용에의한의약품의효능강화법 |
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| US6187799B1 (en) | 1997-05-23 | 2001-02-13 | Onyx Pharmaceuticals | Inhibition of raf kinase activity using aryl ureas |
| US20070244120A1 (en) | 2000-08-18 | 2007-10-18 | Jacques Dumas | Inhibition of raf kinase using substituted heterocyclic ureas |
| GB9823873D0 (en) | 1998-10-30 | 1998-12-30 | Pharmacia & Upjohn Spa | 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents |
| WO2003068229A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
| US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| CA2592118C (en) | 2004-12-23 | 2015-11-17 | Deciphera Pharmaceuticals, Llc | Urea derivatives as enzyme modulators |
| US8188113B2 (en) | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| CL2008001933A1 (es) | 2007-06-29 | 2009-09-25 | Millennium Pharm Inc | Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros. |
| EP2252612B1 (en) | 2008-02-22 | 2012-03-28 | Irm Llc | Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors |
| EP2112150B1 (en) | 2008-04-22 | 2013-10-16 | Forma Therapeutics, Inc. | Improved raf inhibitors |
| JP2012514044A (ja) | 2008-12-30 | 2012-06-21 | ミレニアム ファーマシューティカルズ, インコーポレイテッド | Rafキナーゼ阻害剤として有用なヘテロアリール化合物 |
| AR090151A1 (es) | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
| KR101652229B1 (ko) | 2012-06-07 | 2016-08-30 | 데시페라 파마슈티칼스, 엘엘씨. | 증식성 질환의 치료를 위한 키나제 저해제로서 유용한 다이하이드로나프타이리딘 및 관련 화합물 |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| JP6636014B2 (ja) | 2014-09-12 | 2020-01-29 | ノバルティス アーゲー | Rafキナーゼ阻害剤としての化合物および組成物 |
| CA3107014A1 (en) | 2018-07-31 | 2020-02-06 | AusCann Group Holdings Ltd | Solid self-emulsifying pharmaceutical compositions |
| WO2020168172A1 (en) | 2019-02-15 | 2020-08-20 | Zamboni Chem Solutions Inc. | Conjugate compounds for the degradation of raf |
| CN114072148A (zh) | 2019-05-03 | 2022-02-18 | 金耐特生物制药公司 | Raf激酶的抑制剂 |
| WO2022060996A1 (en) | 2020-09-18 | 2022-03-24 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
| US11377431B2 (en) | 2020-10-12 | 2022-07-05 | Kinnate Biopharma Inc. | Inhibitors of RAF kinases |
| JP7825636B2 (ja) | 2021-04-23 | 2026-03-06 | ピエール ファーブル メディカモン | (s)-n-(3-(2-(((r)-1-ヒドロキシプロパン-2-イル)アミノ)-6-モルホリノピリジン-4-イル)-4-メチルフェニル)-3-(2,2,2-トリフルオロエチル)ピロリジン-1-カルボキサミドおよびその塩の固体状態での形態 |
| TW202308645A (zh) | 2021-04-23 | 2023-03-01 | 美商奇奈特生物製藥公司 | 使用raf抑制劑之癌症治療 |
-
2022
- 2022-04-21 JP JP2023565206A patent/JP7825636B2/ja active Active
- 2022-04-21 WO PCT/US2022/025815 patent/WO2022226221A1/en not_active Ceased
- 2022-04-21 IL IL307910A patent/IL307910A/en unknown
- 2022-04-21 US US18/556,243 patent/US12692248B2/en active Active
- 2022-04-21 MX MX2023012521A patent/MX2023012521A/es unknown
- 2022-04-21 AU AU2022261159A patent/AU2022261159A1/en active Pending
- 2022-04-21 CA CA3216258A patent/CA3216258A1/en active Pending
- 2022-04-21 CN CN202280044060.6A patent/CN117529313A/zh active Pending
- 2022-04-21 EP EP22792520.3A patent/EP4326255A4/en active Pending
- 2022-04-21 KR KR1020237039724A patent/KR20240000540A/ko active Pending
- 2022-04-21 BR BR112023021916A patent/BR112023021916A2/pt unknown
- 2022-04-22 TW TW111115523A patent/TWI922665B/zh active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016038581A1 (en) | 2014-09-12 | 2016-03-17 | Novartis Ag | Compounds and compositions as raf kinase inhibitors |
| WO2020198058A1 (en) | 2019-03-22 | 2020-10-01 | Kinnate Biopharma Inc. | Inhibitors of raf kinases |
| JP7626910B2 (ja) | 2019-10-24 | 2025-02-05 | ピエール ファーブル メディカモン | Rafキナーゼの阻害剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023021916A2 (pt) | 2023-12-19 |
| MX2023012521A (es) | 2023-12-15 |
| US20240208931A1 (en) | 2024-06-27 |
| TW202309018A (zh) | 2023-03-01 |
| JP2024517431A (ja) | 2024-04-22 |
| AU2022261159A1 (en) | 2023-11-23 |
| EP4326255A1 (en) | 2024-02-28 |
| CN117529313A (zh) | 2024-02-06 |
| US12692248B2 (en) | 2026-07-28 |
| IL307910A (en) | 2023-12-01 |
| CA3216258A1 (en) | 2022-10-27 |
| WO2022226221A1 (en) | 2022-10-27 |
| TWI922665B (zh) | 2026-04-21 |
| KR20240000540A (ko) | 2024-01-02 |
| EP4326255A4 (en) | 2025-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024517431A (ja) | (s)-n-(3-(2-(((r)-1-ヒドロキシプロパン-2-イル)アミノ)-6-モルホリノピリジン-4-イル)-4-メチルフェニル)-3-(2,2,2-トリフルオロエチル)ピロリジン-1-カルボキサミドおよびその塩の固体状態での形態 | |
| US20240156804A1 (en) | C-Met Modulator Pharmaceutical Compositions | |
| TW202015698A (zh) | Tlr7/tlr8抑制劑之晶型 | |
| TW201720803A (zh) | 唾液酸或其鹽或溶劑合物之晶型 | |
| WO2018184185A1 (zh) | 奥扎莫德加成盐晶型、制备方法及药物组合物和用途 | |
| WO2014082354A1 (zh) | 西达本胺的晶型及其制备方法与应用 | |
| JP2025131661A (ja) | 2-(5-(4-(2-モルホリノエトキシ)フェニル)ピリジン-2-イル)-n-ベンジルアセトアミドの固体形態 | |
| US20250059170A1 (en) | Solid state forms of an fgfr inhibitor | |
| TW202245746A (zh) | N-((r)-2,3-二羥基丙氧基)—3,4—二氟—2—(2—氟—4—碘—苯基胺基)—苯甲醯胺之基本上純的形式iv之組合物及其用途 | |
| JP2007526229A (ja) | 4−[6−アセチル−3−[3−(4−アセチル−3−ヒドロキシ−2−プロピルフェニルチオ)プロポキシ]−2−プロピルフェノキシ]酪酸の多形形態aの製造方法 | |
| TWI705065B (zh) | 嗎啉衍生物的鹽及其晶型、其製備方法及藥物組成物、用途 | |
| WO2020165807A1 (en) | Solid forms of deutetrabenazine and process for the preparation thereof | |
| CN120344512A (zh) | 氧异吲哚-5-甲酰胺类化合物或其盐、溶剂合物的结晶形式或无定形形式 | |
| CN115536654A (zh) | 小檗碱橙皮素盐晶型及其制备方法和其组合物与应用 | |
| HK40107041A (en) | Solid state forms of (s)-n-(3-(2-(((r)-1-hydroxypropan-2-yl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and salts thereof | |
| US20220389022A1 (en) | Solid forms of ponatinib hydrochloride and process thereof | |
| CA2955397C (en) | Novel crystalline form of 5-chloro-n-({(5s)-2-oxo-3-[4-(5,6-dihydro-4h-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide methanesulfonate and pharmaceutical composition comprising same | |
| US20240270733A1 (en) | Hydrate form of lazertinib mesylate, preparation method thereof and use thereof | |
| WO2026040323A1 (zh) | 一种依鲁替尼单月桂醇硫酸盐、制备方法、应用 | |
| WO2017029408A1 (en) | Solid state forms of sofosbuvir | |
| HK40115548A (en) | Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide | |
| US10759798B2 (en) | ABT-199 addition salt and crystal form thereof, preparation method thereof, and pharmaceutical composition thereof | |
| JP2026503653A (ja) | Df2755aの安定な一水和物およびその調製方法 | |
| CN113631544A (zh) | (s)-2-(7-氰基-1h-苯并咪唑-1-基)-n-{1-[4-(1-氰基-1-甲基乙基)苯基]乙基}乙酰胺的晶型 | |
| HK1213549A1 (en) | Solid salt form of alpha-6-mpeg6-o-hydroxycodone as opioid agonists and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240117 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20241209 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250418 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250418 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20251014 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260113 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260127 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260224 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7825636 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |